The temporal version of the pediatric sepsis biomarker risk model

Hector R. Wong  
*University of Cincinnati*

Scott L. Weiss  
*Children's Hospital of Philadelphia*

John S. Giuliano Jr.  
*Yale University*

Mark S. Wainwright  
*Children's Hospital of Chicago*

Natalie Z. Cvijanovich  
*Children's Hospital & Research Center, Oakland, CA*

*See next page for additional authors*

Follow this and additional works at: [http://hsrc.himmelfarb.gwu.edu/smhs_peds_facpubs](http://hsrc.himmelfarb.gwu.edu/smhs_peds_facpubs)

Part of the [Pediatrics Commons](http://hsrc.himmelfarb.gwu.edu/smhs_peds_facpubs)

**Recommended Citation**


This Journal Article is brought to you for free and open access by the Pediatrics at Health Sciences Research Commons. It has been accepted for inclusion in Pediatrics Faculty Publications by an authorized administrator of Health Sciences Research Commons. For more information, please contact hsrc@gwu.edu.
Authors
Hector R. Wong, Scott L. Weiss, John S. Giuliano Jr., Mark S. Wainwright, Natalie Z. Cvijanovich, Robert J. Freishtat, and +19 additional authors

This journal article is available at Health Sciences Research Commons: http://hsrc.himmelfarb.gwu.edu/smhs_peds_facpubs/681
The Temporal Version of the Pediatric Sepsis Biomarker Risk Model

Hector R. Wong1,2*, Scott L. Weiss3, John S. Giuliano Jr.4, Mark S. Wainwright5, Natalie Z. Cvijanovich6, Neal J. Thomas7, Geoffrey L. Allen8, Nick Anas9, Michael T. Bigham10, Mark Hall11, Robert J. Freishtat12, Anita Sen13, Keith Meyer14, Paul A. Checchia15, Thomas P. Shanley16, Jeffrey Nowak17, Michael Quasney16, Arun Chopra18, Julie C. Fitzgerald3, Rainer Gedeit19, Sharon Banschbach1, Eileen Beckman1, Kelli Harmon1, Patrick Lahni1, Christopher J. Lindsell20

1 Division of Critical Care Medicine, Cincinnati Children’s Hospital Medical Center and Cincinnati Children’s Research Foundation, Cincinnati, Ohio, United States of America, 2 Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, United States of America, 3 The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, United States of America, 4 Division of Critical Care Medicine, Department of Pediatrics, Yale University School of Medicine, New Haven, Connecticut, United States of America, 5 Ann and Robert H. Lurie Children’s Hospital of Chicago, Chicago, Illinois, United States of America, 6 Children’s Hospital and Research Center Oakland, Oakland, California, United States of America, 7 Penn State Hershey Children’s Hospital, Hershey, Pennsylvania, United States of America, 8 Children’s Mercy Hospital, Kansas City, Missouri, United States of America, 9 Children’s Hospital of Orange County, Orange, California, United States of America, 10 Akron Children’s Hospital, Akron, Ohio, United States of America, 11 Nationwide Children’s Hospital, Columbus, Ohio, United States of America, 12 Children’s National Medical Center, Washington, DC, United States of America, 13 Morgan Stanley Children’s Hospital, Columbia University Medical Center, New York, New York, United States of America, 14 Miami Children’s Hospital, Miami, Florida, United States of America, 15 Texas Children’s Hospital, Houston, Texas, United States of America, 16 C S Mott Children’s Hospital at the University of Michigan, Ann Arbor, Michigan, United States of America, 17 Children’s Hospital and Clinics of Minnesota, Minneapolis, Minnesota, United States of America, 18 St. Christopher’s Hospital for Children, Philadelphia, Pennsylvania, United States of America, 19 Children’s Hospital of Wisconsin, Milwaukee, Wisconsin, United States of America, 20 Department of Emergency Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio, United States of America

Abstract

**Background:** PERSEVERE is a risk model for estimating mortality probability in pediatric septic shock, using five biomarkers measured within 24 hours of clinical presentation.

**Objective:** Here, we derive and test a temporal version of PERSEVERE (tPERSEVERE) that considers biomarker values at the first and third day following presentation to estimate the probability of a “complicated course”, defined as persistence of ≥ 2 organ failures at seven days after meeting criteria for septic shock, or death within 28 days.

**Methods:** Biomarkers were measured in the derivation cohort (n = 225) using serum samples obtained during days 1 and 3 of septic shock. Classification and Regression Tree (CART) analysis was used to derive a model to estimate the risk of a complicated course. The derived model was validated in the test cohort (n = 74), and subsequently updated using the combined derivation and test cohorts.

**Results:** A complicated course occurred in 23% of the derivation cohort subjects. The derived model had a sensitivity for a complicated course of 90% (95% CI 78–96), specificity was 70% (62–77), positive predictive value was 47% (37–58), and negative predictive value was 96% (91–99). The area under the receiver operating characteristic curve was 0.85 (0.79–0.90). Similar test characteristics were observed in the test cohort. The updated model had a sensitivity of 91% (81–96), a specificity of 70% (64–76), a positive predictive value of 47% (39–56), and a negative predictive value of 96% (92–99).

**Conclusions:** tPERSEVERE reasonably estimates the probability of a complicated course in children with septic shock. tPERSEVERE could potentially serve as an adjunct to physiological assessments for monitoring how risk for poor outcomes changes during early interventions in pediatric septic shock.


Editor: Lyle L. Moldawer, University of Florida College of Medicine, United States of America

Received December 11, 2013; Accepted February 18, 2014; Published March 13, 2014

Copyright: © 2014 Wong et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: Supported by National Institutes of Health Grants RC1HL100474, RO1GM064619, RO1GM099773, and an Innovation Award from the Center for Technology Commercialization at the Cincinnati Children’s Hospital Research Foundation. Supported in part by an Institutional Clinical and Translational Science Award, NIH/NCRR BUL1 TR000077. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: I have read the journal’s policy and have the following conflicts: Dr. Wong and the Cincinnati Children’s Hospital Research Foundation have submitted a provisional patent application for the biomarker model. PCT/US2013/025233 (published 8/15/13 as WO 2013/119871), entitled “Biomarkers of Septic Shock”, filed 2/7/13 and claiming priority to U.S. Provisional application 61/595,996, filed 2/7/12. Dr. Lindsell is named as a co-inventor in the above patent application. The remaining authors have no competing interests to report. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

* E-mail: hector.wong@cchmc.org
**Introduction**

We previously derived, updated, and validated the pediatric sepsis biomarker risk model (PERSEVERE; PEdiatRic SEpsis biomarkEr Risk modEl) [1,2]. PERSEVERE is based on a decision tree approach. Classification and regression tree (CART) methodology was used to estimate 28-day mortality probability for pediatric septic shock based on a panel of five biomarkers and age, with an area under the receiver operating characteristic curve of 0.88. The biomarkers that were used to derive PERSEVERE were selected objectively based on extensive genome-wide expression studies designed for the discovery of candidate stratification biomarkers [1–4]. Furthermore, the biomarkers were measured from serum samples obtained during the first 24 hours of presentation to the pediatric intensive care unit (PICU) with septic shock, which is a clinically relevant time period for assigning mortality risk in this heterogeneous population.

While the ability of PERSEVERE to assign a reliable mortality probability during the initial stages of septic shock has inherent utility at multiple levels, it fails to consider temporal changes in biomarker levels, and how these temporal changes may further inform the estimation of risk for poor outcome. This is important because the natural history of septic shock is intrinsically dynamic and subject to change in response to therapy [5–7]. Consequently, the risk for poor outcome also changes over time and it is biologically plausible that temporal changes in the PERSEVERE biomarkers may reflect this change.

In the current study we have derived a temporal version of PERSEVERE (tPERSEVERE), which incorporates biomarker measurements at two time points during the initial three days of illness to estimate the probability of a poor outcome termed “complicated course”. We subsequently test the prognostic accuracy of tPERSEVERE in an independent test cohort.

**Methods**

**Ethics Statement**

The Institutional Review Boards (IRB) of each participating institution approved secondary use of biological specimens and clinical data: Cincinnati Children’s Hospital Medical Center, The Children’s Hospital of Philadelphia, Yale University School of Medicine, Ann & Robert H. Lurie Children’s Hospital of Chicago, Children’s Hospital and Research Center Oakland, Penn State Hershey Children’s Hospital, Children’s Mercy Hospital, Children’s Hospital of Orange County, Akron Children’s Hospital, Nationwide Children’s Hospital, Children’s National Medical Center, Morgan Stanley Children’s Hospital, Columbia University Medical Center, Miami Children’s Hospital, Texas Children’s Hospital, CS Mott Children’s Hospital at the University of Michigan, St. Christopher’s Hospital for Children, and Children’s Hospital of Wisconsin. Written consent was obtained from the parents or legal guardians of all subjects enrolled, unless stated otherwise.

**Derivation Cohort Study Subjects**

Seventeen institutions contributed biological specimens and clinical data to a central repository, with approval from the Institutional Review Boards of each participating institution. Data collection methods were previously described in detail [1,8]. Briefly, children ≤10 years of age admitted to the PICU and meeting pediatric-specific criteria for septic shock were eligible for enrollment. After informed consent from parents or legal guardians, serum samples were obtained within 24 hours of initial presentation to the PICU with septic shock; these are referred to as “day 1” samples. Forty-eight hours after obtaining day 1 samples, a second serum sample was obtained if possible; these are referred to as “day 3” samples. Of the 355 subjects in the original PERSEVERE derivation and validation cohorts, there were 225 with biomarker data available for both day 1 and day 3. The current analysis included these 225 subjects, all of whom were enrolled between May 2002 and August 2010.

The 130 subjects excluded because day 3 biomarker data were not available were enrolled between May 2005 and December 2011. The mortality rate among the excluded subjects (19.2%) was significantly higher than that of the included subjects. Among the excluded subjects who died, 56% of the deaths occurred before day 3. The excluded and included subjects were otherwise not significantly different with respect to age, pediatric risk of mortality (PRISM) score, and incidence of a complicated course.

**Test Cohort Study Subjects**

The test cohort subjects were pooled from four sources, with approval from the respective Institutional Review Boards. Thirty-three subjects were included from an ongoing genomics study in pediatric septic shock being conducted at 17 participating institutions [8–17]. The enrollment criteria are identical to those for the derivation cohort. The current analysis included subjects enrolled between September 2011 and May 2013, which represents subjects enrolled after the original derivation and validation of PERSEVERE.

Eleven subjects were included from among those enrolled in a prospective quality improvement program at one institution. This institution uses PERSEVERE to benchmark outcomes for all patients admitted to the PICU with septic shock. Enrollment procedures are identical to those described above, except that there is no age restriction and the Institutional Review Board of Cincinnati Children’s Hospital Medical Center granted permission for waiver of informed consent. Serum samples were collected from residual blood samples in the clinical laboratory. Subjects from this source were enrolled between September 2012 and May 2013.

Nineteen subjects (age range: 8 days to 18 years) were participants in a prospective, observational study at Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, Illinois, evaluating nitric oxide metabolism and mitochondrial function in children with septic shock [18]. Of the 30 subjects with septic shock enrolled in that study, 19 had serum samples available for analysis. The current analysis included subjects enrolled between May 2009 and June 2010.

Eleven subjects (age range: 2 to 20 years old) were participants in a prospective, observational study at Yale-New Haven Children’s Hospital, New Haven, Connecticut, evaluating angiotensin levels in children with septic shock [19]. Of the 17 subjects with septic shock enrolled in that study, 11 had serum samples available for analysis. The current analysis included subjects enrolled between September 2009 and December 2011.

**Study Procedures**

For all studies, annotated clinical and laboratory data were collected daily while the participant was in the PICU. Illness severity was assessed at the time of presentation using the PRISM score [20]. The number of organ failures during the initial 7 days of PICU admission was recorded using pediatric-specific criteria [21]. All-cause mortality was tracked for 28 days after meeting criteria for septic shock. Our composite endpoint termed “complicated course”, is defined as persistence of two or more organ failures at seven days after meeting criteria for septic shock,
or death within 28 days of presentation, as previously described [22–24].

Biomarkers

PERSEVERE includes C-C chemokine ligand 3 (CCL3), interleukin 8 (IL8), heat shock protein 70 kDa 1B (HSPA1B), granzyme B (GZMB), and matrix metalloepitidase 8 (MMP8). Serum concentrations of these biomarkers were measured using a multi-plex magnetic bead platform (MILLIPLEX MAP) designed for this project by the EMD Millipore Corporation (Billerica, MA). Biomarker concentrations were measured in a Luminex 100/200 System (Luminex Corporation, Austin, TX), according the manufacturers’ specifications. Assay performance data were previously published [1].

Statistical Analysis

Initially, data are described using medians, interquartile ranges, frequencies, and percentages. Comparisons between groups used the Mann-Whitney U-test, Chi-square, or Fisher’s Exact tests as appropriate. Descriptive statistics and comparisons used SigmaStat Software (Systat Software, Inc., San Jose, CA).

CART analysis was used to derive tPERSEVERE (Salford Predictive Modeler, v7.0, Salford Systems, San Diego, CA) [1,2,25,26]. The primary outcome variable for the modeling procedures is complicated course. The absolute day 1 and day 3 biomarker values, the percentage change in biomarker values from day 1 to day 3, and age were considered in the modeling procedures. Weighting of cases and the addition of cost for misclassification were not used in the modeling procedures. The code used to generate the model is available from the authors. Performance of the derived model is reported using diagnostic test statistics with 95% confidence intervals computed using the score method as implemented by the VassarStats Website for Statistical Computation [27].

Results

Derivation of tPERSEVERE

Table 1 shows the demographic and clinical characteristics of the derivation cohort (n = 225). The 52 (23%) subjects with a complicated course had a higher median PRISM score and were less likely to have a causative organism isolated compared to the 173 subjects with a non-complicated course. No other differences were observed.

Figure 1 shows the derived model. Maximum accuracy was achieved with five biomarker variables: absolute day 1 IL8 and CCL3 values; and absolute day 3 IL8, CCL3, and HSPA1B values. None of the other biomarker variables or age contributed to predictive accuracy. There were four low probability terminal nodes for a complicated course (0.0 to 7.9% probability; terminal nodes TN1, TN2, TN4, and TN6) and four high probability terminal nodes (35.3 to 57.9% probability; TN3, TN5, TN7, and TN8). Among the 168 subjects classified as low probability, 162 (96%) had a non-complicated course and six (4%) had a complicated course. Among the 50 subjects classified as low probability for a poor outcome, then some of the false positives (which lower the positive predictive value and specificity) likely represent patients in whom interventions are beneficial and can ameliorate the risk of a poor outcome, while the high negative predictive value allows one to reliably identify patients at risk for a poor outcome, while the high negative predictive value allows one to identify those who are low risk.

Testing tPERSEVERE

The independent test cohort consisted of 74 subjects with septic shock, of whom 16 (22%) had a complicated course. Table 1 shows the demographics and clinical characteristics of the test cohort. Compared to the derivation cohort, the test cohort subjects had a higher median age, and a higher proportion had no race reported, no causative organism isolated, and malignancy. Within the test cohort, the subjects with a complicated course had a lower proportion of males, compared to the subjects with a non-complicated course. No other differences were observed.

The test cohort subjects were classified according to the derived model. Among the 50 subjects classified as low probability for a complicated course, 47 (94%) had a non-complicated course and three (6%) had a complicated course. Among the 24 subjects classified as high probability, 13 (54%) had a complicated course.

The temporal version of PERSEVERE (tPERSEVERE) reasonably estimates the risk of a complicated course in a heterogeneous cohort of children with septic shock. The study subjects were drawn from multiple centers and pooled from four distinct databanks, thus adding substantial variability with regard to pathology and therapeutic interventions. Despite the concern that such heterogeneity might diminish the accuracy of predictions, tPERSEVERE performed reliably. This suggests that tPERSEVERE will be generalizable upon further testing. We note that the positive predictive value of tPERSEVERE is substantially lower than the negative predictive value. The positive and negative predictive values of a diagnostic test are influenced by the prevalence of the outcome of interest [3]. In this study, the prevalence of a complicated course was about 23%, so one would expect that the positive predictive value would be lower than the negative predictive value. Further, if one assumes that therapeutic interventions are beneficial and can ameliorate the risk of a poor outcome, then some of the false positives (which lower the positive predictive value and specificity) likely represent patients in whom the predicted poor outcome was prevented by therapeutic interventions.

The high sensitivity allows one to reliably identify patients at risk for a poor outcome, while the high negative predictive value allows one to identify those who are low risk. Indeed, a dichotomous interpretation of the model is that it can be used to divide a heterogeneous cohort of children with septic shock into two groups that differ by a factor of ten in the probability of a poor outcome. An alternative interpretation of the model is to view each terminal node individually, which allows for the assignment of a range of probabilities for a complicated course.
In the current study, we focused our modeling procedures on a composite outcome variable, complicated course, whereas in our previous studies we focused on 28-day mortality [1,2]. There are two primary reasons for this change in focus. First, while 28-day mortality is an important outcome variable, mortality alone does not fully capture all septic shock-associated morbidity. Organ failure has been associated with poor functional outcomes in septic shock survivors [23], and so the composite variable used in this study has been recently proposed as a clinically relevant study endpoint [22,23]. Second, the incidence of mortality in the study cohorts was too low for reliable modeling. We note that in the initially derived tPERSEVERE, 49% of the derivation cohort subjects and 47% of the test cohort subjects occupy terminal nodes 1 and 8, which are dependent only on day 1 data. However, in the updated model, there is only one terminal node that is dependent exclusively on day 1 data (TN1), and only 28% of the subjects occupy this node. The remaining terminal nodes are informed by both day 1 and day 3 biomarker data. This suggests that as we accrue more data pertaining to changing biomarkers, we may continue to improve our ability to both predict risk and monitor therapeutic effect.

We note the limitations of our study. The test cohort, while representative of the general pediatric septic shock population, is relatively small. There is potential for selection bias in the absence of PERSEVERE, does not capture early septic shock mortality (i.e., <3 days).

In conclusion, we have derived, tested, and updated a temporal version of PERSEVERE. Pending further prospective validation, we propose that tPERSEVERE has potential to serve as an adjunct to physiological assessments for monitoring how risk for poor outcomes changes during the period of early intervention in

### Table 1. Demographics and clinical characteristics of the derivation and test cohorts (CC = complicated course).

<table>
<thead>
<tr>
<th></th>
<th>Derivation Cohort</th>
<th>Test Cohort</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>All</td>
<td>Non-CC</td>
</tr>
<tr>
<td>N</td>
<td>225</td>
<td>173</td>
</tr>
<tr>
<td>Mortality (%)</td>
<td>7</td>
<td>0</td>
</tr>
<tr>
<td>Median age years</td>
<td>2.3</td>
<td>2.4</td>
</tr>
<tr>
<td>(IQR)</td>
<td>(0.8–5.6)</td>
<td>(1.0–6.0)</td>
</tr>
<tr>
<td>Median PRISM score</td>
<td>14</td>
<td>12</td>
</tr>
<tr>
<td>(IQR)</td>
<td>(9–21)</td>
<td>(8–18)</td>
</tr>
<tr>
<td>Males # (%)</td>
<td>141 (63)</td>
<td>105 (61)</td>
</tr>
<tr>
<td>Females # (%)</td>
<td>84 (37)</td>
<td>68 (39)</td>
</tr>
<tr>
<td>Caucasian # (%)</td>
<td>160 (71)</td>
<td>126 (73)</td>
</tr>
<tr>
<td>African American # (%)</td>
<td>37 (16)</td>
<td>28 (16)</td>
</tr>
<tr>
<td>Other Race # (%)</td>
<td>13 (6)</td>
<td>9 (5)</td>
</tr>
<tr>
<td>Unreported Race # (%)</td>
<td>15 (7)</td>
<td>10 (6)</td>
</tr>
<tr>
<td>Gram+bacteria # (%)</td>
<td>61 (27)</td>
<td>43 (25)</td>
</tr>
<tr>
<td>Gram - bacteria # (%)</td>
<td>64 (28)</td>
<td>45 (26)</td>
</tr>
<tr>
<td>Viral infection # (%)</td>
<td>23 (10)</td>
<td>15 (9)</td>
</tr>
<tr>
<td>Fungal infection # (%)</td>
<td>3 (1)</td>
<td>2 (1)</td>
</tr>
<tr>
<td>No organism # (%)</td>
<td>82 (36)</td>
<td>71 (41)</td>
</tr>
<tr>
<td>Any co-morbidity (%)</td>
<td>98 (44)</td>
<td>78 (45)</td>
</tr>
<tr>
<td>Malignancy # (%)</td>
<td>16 (7)</td>
<td>14 (8)</td>
</tr>
<tr>
<td>Imunosuppression # (%)</td>
<td>32 (14)</td>
<td>28 (16)</td>
</tr>
</tbody>
</table>

1 Nineteen subjects (15 with a non-complicated course and 4 with a complicated course) in the test cohort did not have available PRISM scores.
2 p<0.05 vs. derivation cohort subjects with a non-complicated course.
3 p<0.05 vs. derivation cohort.
4 Refers to patients with immune suppression not related to cancer (for example, those receiving immune suppressive medication for solid organ or bone marrow transplantation, or those with a primary immune deficiency).

doi:10.1371/journal.pone.0092121.t001

©PERSEVERE.
Figure 1. Classification tree from the derivation cohort (N = 225). The classification tree consists of 7 biomarker-based decision rules and 14 daughter nodes. The classification tree includes day 1 and day 3 data for interleukin-8 (IL8) and C-C chemokine ligand 3 (CCL3), and day 3 data heat shock protein 70 kDa 1B (HSPA1B). Each node provides the biomarker serum concentration-based decision rule, and the number of subjects with and without complicated course (CC), with the respective rates. For consistency, the serum concentrations of all biomarkers are provided in pg/ml. Terminal nodes (TN) 1, 2, 4, and 6 are considered low risk nodes, whereas terminal nodes 3, 5, 7, and 8 are considered high-risk terminal nodes. To calculate the diagnostic test characteristics, all subjects in the low risk terminal nodes (n = 126) were classified as predicted to not have a complicated course, whereas all subjects in the high risk terminal nodes (n = 99) were classified as predicted to have a complicated course.

doi:10.1371/journal.pone.0092121.g001

Table 2. Test characteristics of the decision tree.

<table>
<thead>
<tr>
<th></th>
<th>Derivation Cohort</th>
<th>Test Cohort</th>
<th>Updated Model</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of Subjects</td>
<td>225</td>
<td>74</td>
<td>299</td>
</tr>
<tr>
<td>Number of True Positives</td>
<td>47</td>
<td>13</td>
<td>62</td>
</tr>
<tr>
<td>Number of True Negatives</td>
<td>121</td>
<td>47</td>
<td>162</td>
</tr>
<tr>
<td>Number of False Positives</td>
<td>52</td>
<td>11</td>
<td>69</td>
</tr>
<tr>
<td>Number of False Negatives</td>
<td>5</td>
<td>3</td>
<td>6</td>
</tr>
<tr>
<td>Sensitivity</td>
<td>90% (78–96)</td>
<td>81% (54–95)</td>
<td>91% (81–96)</td>
</tr>
<tr>
<td>Specificity</td>
<td>70% (62–77)</td>
<td>81% (68–90)</td>
<td>70% (64–76)</td>
</tr>
<tr>
<td>Positive Predictive Value</td>
<td>47% (37–58)</td>
<td>54% (33–74)</td>
<td>47% (39–56)</td>
</tr>
<tr>
<td>Negative Predictive Value</td>
<td>96% (91–99)</td>
<td>94% (82–98)</td>
<td>96% (92–99)</td>
</tr>
<tr>
<td>+Likelihood Ratio</td>
<td>3.0 (2.4–3.8)</td>
<td>4.3 (2.4–7.7)</td>
<td>3.1 (2.5–3.8)</td>
</tr>
<tr>
<td>–Likelihood Ratio</td>
<td>0.1 (0.1–0.3)</td>
<td>0.2 (0.1–0.6)</td>
<td>0.1 (0.1–0.3)</td>
</tr>
<tr>
<td>Area Under the Curve</td>
<td>0.85 (0.79–0.90)</td>
<td>0.83 (0.74–0.93)</td>
<td>0.84 (0.79–0.89)</td>
</tr>
</tbody>
</table>

doi:10.1371/journal.pone.0092121.t002
children with septic shock, or to serve as a surrogate outcome variable in clinical trials.

Acknowledgments

The authors thank the following research coordinators for their effort and dedication in enrolling study participants: Tasha Capozzi, Mary Ann De Liberto, Mercedes Gálera-Perez, Kristin Greathouse, Lauren Hoadley, Katherine Luther, Stephanie Osborne, Amber Hughes-Schalk, Tonia Polanski, Julie Simon, Debra Spear, Lisa Steele, Naresh B. Talathoti, Tiffany Vertican, Monica Weber, Andrew A. Wiles, Trisha Williams, and Erin Zielinski.

Author Contributions

Conceived and designed the experiments: HRW CJL. Performed the experiments: SB EB KH PL. Analyzed the data: HRW CJL. Contributed reagents/materials/analysis tools: SLW JSG MSW NZC NJT GLA NA MTB MH RJF AS KM PAC TPS JN MQ AC JCF RG. Wrote the paper: HRW CJL. Read and edited the manuscript: HRW SLW JSG MSW NZC NJT GLA NA MTB MH RJF AS KM PAC TPS JN MQ AC JCF RG SB EB KH PL CJL.

References


